Načítá se...
Sacubitril–valsartan in heart failure and multimorbidity patients
AIMS: The poor control of symptoms in patients with advanced heart failure with reduced ejection function (HFrEF) can limit the functionality of patients. Sacubitril–valsartan, compared with enalapril, has been shown to reduce mortality and hospitalization, and nowadays, there is still little eviden...
Uloženo v:
| Vydáno v: | ESC Heart Fail |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6165940/ https://ncbi.nlm.nih.gov/pubmed/30039930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12338 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|